QPS competitors

Dr. Ellison has served as our President and Chief Executive Officer since April 2020 and as a Director on our Board since January 2020. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc. (acquired by Roche); President and Chief Executive Officer of Bond Biosciences, Inc., a biotech start-up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC, a life sciences investment banking firm; Chairman and Chief Executive Officer of Assembly Biosciences, Inc. (formerly Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, a global drug development and healthcare investment firm; Vice President of Clinical Development of FibroGen, Inc., where he played a key role in the early phase development of roxadustat in anemia for chronic kidney disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo US, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc. in the United States. Dr. Ellison previously served as an Independent Board Director for several private and public companies, including Cougar Biotechnology Inc.; ProSanos Corporation; Cormedix Inc., a cardio-renal clinical stage company; and Mt. Cook, a urology-focused company. Dr. Ellison received a Master of Science degree from the London School of Tropical Medicine and Hygiene, and an M.D. from the University of British Columbia.

Salim Haffar has been President of Aptar Pharma since January 2014. Previously, he served as President of Aptar Pharma's Prescription Division and Co-President of Valois Group and President of Valois' Pharma division. Prior to 2008, Salim held various sales and marketing positions within the Company's Valois Pharma division in France.

Michael Petras is president of AssuraMed, a leading mail-order, direct-to-customer provider of disposable medical products to chronic disease patients that was acquired by Cardinal Health in March 2013 and is currently being integrated into the Medical Segment. Prior to joining AssuraMed, Petras worked for Connecticut-based General Electric where he served as president and Chief Executive Officer of GE Lighting. During his more than 18 years at GE, he held positions within Product Management, Six Sigma Quality and Sales. Petras is a board member of The Cleveland Foundation and John Carroll University and serves on The Cleveland Clinic’s Board of Trustees. He is also a past board member of Achievement Centers for Children, United Way of Cleveland and the Greater Cleveland Partnership. He holds a bachelor’s degree in finance from John Carroll University and a Master’s in Business Administration in marketing from Case Western Reserve University.

Cynthia LaConte is a Trustee at Mount Mary University, Chief Executive Officer at Red Arrow Labs, and Chief Executive Officer at Dohmen and is based in Milwaukee, Wisconsin. She has worked as Chief Operating Officer at Dohmen, Chief Executive Officer at DOHMEN LIFE SCIENCE SERVICES, and President at DDN Pharmaceutical Logistics. Cynthia studied at Mount Mary University.

Marc Ayers is a co-founder of the company. Prior to founding Romark, he spent seven years as a certified public accountant in the tax consulting practice of KPMG Peat Marwick in Tampa, Florida, and then five years as an investment banker, where he gained experience in working with the pharmaceutical industry. Mr. Ayers studied accounting, economics and finance, graduating summa cum laude with a Master's degree in Taxation from the University of Alabama in 1981.

Gregory Pulido is a Chairman and Chief Executive Officer at HUMCO and is based in Austin, Texas. He studied at Arizona State University.